{"aliases":[{"type":"Synonym","name":"herpes zoster vaccine 1437173A"},{"type":"CodeName","name":"1437173A"},{"type":"CodeName","name":"GSK 1437173A"},{"type":"CodeName","name":"GSK1437173A"},{"type":"Synonym","name":"herpes zoster subunit vaccine GSK 1437173A"},{"type":"Synonym","name":"HZ/su vaccine GSK 1437173A"},{"type":"USBrandName","name":"Shingrix"}],"definition":{"html":"A recombinant, subunit herpes zoster (HZ) vaccine containing varicella-zoster virus (VZV) glycoprotein E (gE), that can potentially be used to prevent HZ infection, also called shingles. Upon administration, zoster vaccine recombinant, adjuvanted stimulates the host immune system to induce both specific CD4-positive T-cells and antibodies against VZV gE, thereby protecting against infection with HZ. VZV gE, the most common antigen in VZV viral particles, plays a key role in VZV infection. Compared to live-attenuated vaccines, the subunit vaccine prevents the risk of vaccine-induced HZ in immunocompromised patients. ","text":"A recombinant, subunit herpes zoster (HZ) vaccine containing varicella-zoster virus (VZV) glycoprotein E (gE), that can potentially be used to prevent HZ infection, also called shingles. Upon administration, zoster vaccine recombinant, adjuvanted stimulates the host immune system to induce both specific CD4-positive T-cells and antibodies against VZV gE, thereby protecting against infection with HZ. VZV gE, the most common antigen in VZV viral particles, plays a key role in VZV infection. Compared to live-attenuated vaccines, the subunit vaccine prevents the risk of vaccine-induced HZ in immunocompromised patients. "},"drugInfoSummaryLink":null,"nciConceptId":"C88288","nciConceptName":"Zoster Vaccine Recombinant, Adjuvanted","termId":657270,"name":"zoster vaccine recombinant, adjuvanted","firstLetter":"z","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"zoster-vaccine-recombinant-adjuvanted"}